Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study
Autor: | Kurt Possinger, G. Köhler, Volker Heilmann, Peter Schmid, J. Krocker, D. Elling, T. Schaller-Kranz, Jens Uwe Blohmer, G. Morack, K. Michniewicz |
---|---|
Rok vydání: | 2004 |
Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Neutropenia Paclitaxel medicine.medical_treatment Phases of clinical research Breast Neoplasms Drug Administration Schedule chemistry.chemical_compound Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Stomatitis Aged Neoplasm Staging Chemotherapy business.industry General Medicine Middle Aged medicine.disease Primary tumor Surgery Treatment Outcome chemistry Female business medicine.drug |
Zdroj: | Journal of cancer research and clinical oncology. 130(11) |
ISSN: | 0171-5216 |
Popis: | To assess the efficacy and safety of primary systemic treatment with doxorubicin and paclitaxel in patients with early breast cancer. Forty patients with newly diagnosed, histologically confirmed breast cancer (T2, N0–1, M0) received primary chemotherapy with doxorubicin (60 mg/m2) and paclitaxel (200 mg/m2) in 3-week intervals for up to four courses. A total of 151 cycles were administered. The clinical response rate as assessed by sonographic measurement was 70%, and complete remissions of the primary tumor occurred in two patients. Eight patients (20%) had histologically confirmed complete responses. Predominant toxicity was myelosuppression with grade 3/4 neutropenia in 70% of patients. Non-hematological toxicity was generally moderate. Grade 4 non-hematological toxicities were not observed and grade 3 toxicity was reported with alopecia (98%) and stomatitis (10%). The combination of doxorubicin and paclitaxel is safe and highly active in patients with early breast cancer. The evaluated schedule is suitable for phase III studies. |
Databáze: | OpenAIRE |
Externí odkaz: |